AB-free kava
Phase 2Small molecule
AB-free kava is one of 43 small molecule programs targeting Adults. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Insomnia
#DrugCompanyPhaseTrials
1Rozerem
TakedaApproved
Dayvigo
EisaiApproved
Ambien
PPurdue Pharma LP
Approved
Lunesta
Akero TherapeuticsApproved
Lexapro
AbbVieApproved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Raldesy
PPragma
Approved
Quviviq
Idorsia Pharmaceuticals Ltd.Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Bayer Aspirin
BayerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AB-free kava. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Florida